| Literature DB >> 11908720 |
Jolanta Perz1, Julian Topaly, Stefan Fruehauf, Manfred Hensel, Anthony D Ho.
Abstract
Rituximab (IDEC C2B8) is a chimeric human-mouse monoclonal anti-CD20 antibody that has been proven to be effective for the treatment of patients with CD20 positive leukemia and lymphoma. The level of CD20-expression in patients with B-cell chronic lymphocytic leukemia (B-CLL) is low in comparison to other B-cell lymphomas and normal B-cells. Previous experience with rituximab treatment in small series of patients with B-CLL suggest that it is less effective in B-CLL than in follicular lymphomas. We analyzed the correlation between CD20-expression level and efficacy of rituximab treatment in eight patients with refractory or relapsed B-CLL and two patients with B-cell prolymphocytic leukemia (B-PLL). We could not identify any correlation between CD20-expression and efficacy of rituximab treatment.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11908720 DOI： 10.1080/10428190210178
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022